Loading rounds…
Loading rounds…
Explore funding rounds, the companies behind them and the investors taking part.
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| ND New Dawn BioCompany profile Grows cultured wood from tree stem cells in bioreactors, eliminating the need for logging Grows cultured wood from tree stem cells in bioreactors, eliminating the need for logging | €2.1M | Pre-SeedPre-seed | Biotech, Climate tech | Netherlands | Investors | |
| AB ARTAN BioCompany profile Develops mutation-specific codon suppression technologies to address genetic diseases and aging-related conditions |
Ranked by rounds participated in · All time
AusperBio, Abcuro, Infinimmune
Epicrispr Biotechnologies, Draig Therapeutics, Triveni Bio
LifeMine Therapeutics, Ollin Biosciences, SonoThera
Leal Therapeutics, Khartis Therapeutics, Vedana Therapeutics
Leal Therapeutics, Amplifica Holdings Group, InduPro
Explore published rounds while the next edition is being prepared.
Develops mutation-specific codon suppression technologies to address genetic diseases and aging-related conditions
| $200K |
| Seed |
| Biotech |
| United States |
| Investors |
| GT Goldenrod TherapeuticsCompany profile Develops novel brain-penetrant therapies targeting neuroinflammation and neuronal signaling pathways Develops novel brain-penetrant therapies targeting neuroinflammation and neuronal signaling pathways | $6.5M | Seed | Biotech | United States | Investors |
| S ScispotCompany profile Provides an AI-native operating layer for life sciences labs to automate work and track samples Provides an AI-native operating layer for life sciences labs to automate work and track samples | $8M | Series A | Biotech | Canada | Investors |
| I IngenixCompany profile Builds AI architecture fusing biological data modalities to accelerate pharma and biotech drug development Builds AI architecture fusing biological data modalities to accelerate pharma and biotech drug development | €13M | Seed+Seed | Biotech | Poland | Investors |
| A ApohaCompany profile Measures molecular behaviour at scale to help pharma, food, and materials companies predict real-world product performance Measures molecular behaviour at scale to help pharma, food, and materials companies predict real-world product performance | $36M | Series A | Biotech, Industrial tech | United Kingdom | Investors |
| IH Ilant HealthCompany profile Delivers AI-enabled, value-based obesity and cardiometabolic care to employers and health plans Delivers AI-enabled, value-based obesity and cardiometabolic care to employers and health plans | $15M | Series A | Biotech, Healthtech | United States | Investors |
| AN Advanced NanoTherapiesCompany profile Developing a nanoparticle platform for local dual-drug delivery during catheter-based vascular interventions Developing a nanoparticle platform for local dual-drug delivery during catheter-based vascular interventions | >$31M | Series B | Biotech, Healthtech | United States | Investors |
| IB IMU BiosciencesCompany profile Profiles the human immune system at scale using multi-omic analysis and machine learning to transform disease diagnosis and treatment Profiles the human immune system at scale using multi-omic analysis and machine learning to transform disease diagnosis and treatment | $53M | Series A | Biotech | United Kingdom | Investors |
| TB Develops novel therapeutics for glaucoma and retinal diseases | $17M | Series A | Biotech | United States | Investors |